{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreihjsk2jnk2it4ll7vct66rhit4opprdzlrcrq454b2k4spvej7pwe",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mihszuwlhui2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreihnoiit2jb3woovsnbdn4zyhxgudrzijdhdjpztsjaeym7fzj3zr4"
    },
    "mimeType": "image/jpeg",
    "size": 554244
  },
  "path": "/news/2026-04-therapy-term-outcomes-patients-rare.html",
  "publishedAt": "2026-04-01T17:20:06.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "In some non-small cell lung cancers (NSCLCs), changes to the RET gene (known as RET fusions) can drive tumor growth. In a phase 1/2 clinical study with a 42-month-long follow-up period, researchers from Mass General Brigham Cancer Institute recently evaluated the long-term efficacy and safety of the FDA-approved drug pralsetinib, which targets RET. Investigators found that treatment led to durable responses with manageable safety profiles in 281 patients with advanced or metastatic RET fusion-positive NSCLCs. Results are published in the Journal of Clinical Oncology.",
  "title": "Targeted therapy improves long-term outcomes for patients with rare mutations driving lung cancer"
}